We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.01%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.04B
AUM Growth
-$325M
Cap. Flow
-$209M
Cap. Flow %
-2.31%
Top 10 Hldgs %
81.82%
Holding
98
New
4
Increased
11
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$78.4M
2
PCVX icon
Vaxcyte
PCVX
+$47.3M
3
INSM icon
Insmed
INSM
+$28.6M
4
IMCR icon
Immunocore
IMCR
+$24.2M
5
CELC icon
Celcuity
CELC
+$17.9M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$171M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$27.7M
3
KRYS icon
Krystal Biotech
KRYS
+$26.6M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$26.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.87%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
76
Tectonic Therapeutic
TECX
$536M
$1.77M 0.02%
+100,000
New +$3.26M
VTVT icon
77
vTv Therapeutics
VTVT
$124M
$1.69M 0.02%
97,314
– –
CMPX icon
78
Compass Therapeutics
CMPX
$349M
$1.04M 0.01%
547,498
-1,010,132
-65% -$2.69M
NMRA icon
79
Neumora Therapeutics
NMRA
$306M
$1.03M 0.01%
1,034,600
– –
HOOK
80
DELISTED
HOOKIPA Pharma
HOOK
$878K 0.01%
812,814
– –
GBIO
81
DELISTED
Generation Bio
GBIO
$788K 0.01%
194,495
– –
ALGS icon
82
Aligos Therapeutics
ALGS
$26.3M
$685K 0.01%
83,055
– –
CYPH
83
Cypherpunk Technologies Inc
CYPH
$64M
$123K ﹤0.01%
404,744
-767,431
-65% -$845K
IPSC icon
84
Century Therapeutics
IPSC
$364M
$115K ﹤0.01%
241,684
-555,776
-70% -$418K
TYRA icon
85
Tyra Biosciences
TYRA
$1.85B
$98.6K ﹤0.01%
10,607
– –
ACRV icon
86
Acrivon Therapeutics
ACRV
$61.2M
$46.3K ﹤0.01%
22,809
-30,076
-57% -$162K
SRZNW icon
87
Surrozen Inc Warrant
SRZNW
$36.6K
$25K ﹤0.01%
833,333
– –
ARCT icon
88
Arcturus Therapeutics
ARCT
$165M
– –
-151,329
Closed -$2.57M
ARVN icon
89
Arvinas
ARVN
$530M
– –
-405,576
Closed -$7.77M
BMEA icon
90
Biomea Fusion
BMEA
$88.2M
– –
-1,451,990
Closed -$5.63M
FHTX icon
91
Foghorn Therapeutics
FHTX
$278M
– –
-45,027
Closed -$213K
KRYS icon
92
Krystal Biotech
KRYS
$10.7B
– –
-169,934
Closed -$26.6M
MIRM icon
93
Mirum Pharmaceuticals
MIRM
$6.56B
– –
-190,476
Closed -$7.88M
MRSN
94
DELISTED
Mersana Therapeutics
MRSN
– –
-43,445
Closed -$1.55M
PMVP icon
95
PMV Pharmaceuticals
PMVP
$57.1M
– –
-322,024
Closed -$486K
PTCT icon
96
PTC Therapeutics
PTCT
$6.18B
– –
-20,400
Closed -$921K
OPT
97
DELISTED
Opthea Limited American Depositary Shares
OPT
$0 ﹤0.01%
2,087,320
-86,302
-4% -$382K
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Baker Bros. Advisors held 98 positions worth $9.04B, down 3.5% from $9.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q1 2025 filing shows 4 new, 11 increased, 16 reduced and 9 closed positions. Its largest new stake was Verona Pharma: 223,843 shares worth $14.2M. The largest sale was BeOne Medicines Ltd, an estimated $171M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2025 buy was Verona Pharma: 223,843 shares worth $14.2M.
  • Baker Bros. Advisors added most to Immunovant in Q1 2025, an estimated $78.4M increase.
  • Baker Bros. Advisors's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $171M.
  • Baker Bros. Advisors fully exited Krystal Biotech in Q1 2025, selling an estimated $26.6M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $9.04B portfolio in Q1 2025.
  • Baker Bros. Advisors opened 4 new positions and closed 9 in Q1 2025.
  • Baker Bros. Advisors's portfolio value fell 3.5% quarter-over-quarter to $9.04B.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.